TOP TALENT FROM DIVERSE BACKGROUNDS

Filter View:

BOARD OF DIRECTORS

Headshot of Masayuki Kobayashi

Masayuki Kobayashi

PRESIDENT & REPRESENTATIVE DIRECTOR

Taiho Pharmaceutical Co., Ltd.

Masa has held the position of President since April 2012, having joined Taiho Pharmaceutical Co., Ltd. in 1993. In his over 25 years with the organization, he considers the formation of Taiho Oncology Inc., his greatest accomplishment, and is most proud of his role as head of Taiho Global. He brings a background in political and law studies, as well as his extensive business experience.

Beyond his position at Taiho, Masa works with a variety of other organizations. He currently serves as Vice Chairman of the Pharmaceutical Association of Tokushima Prefecture in Japan, Committee Member of the Japan Pharmaceutical Manufacturers Association, and Councilor at the Federation of Pharmaceutical Manufacturers in Japan, Pharmaceutical Manufacturers Association of Tokyo, and the Kobayashi Foundation for Cancer Research.

Headshot of Tim Whitten

Tim Whitten

President & CEO

Taiho Oncology, Inc.

Tim assumed the role of President & CEO in May 2018, having joined Taiho Pharma U.S.A., Inc. in February 2013 as Chief Commercial Officer. He is uniquely suited to the role, with an MBA and a pharmacy degree. Before joining Taiho, he served as President & CEO of Insmed, Inc., working to help patients with rare and serious lung diseases. Prior to Insmed, he was the President & CEO of Transave, Inc., and held senior management positions at Pharmacyclics and Bristol-Myers Squibb.

As the company’s first commercial hire, Tim oversaw the creation of the US commercial and Canadian businesses, with successful launches of LONSURF® (trifluridine and tipiracil) in both markets. Under his leadership, Taiho’s North American oncology commercial...

U.S. LEADERSHIP TEAM

Taiho Oncology’s U.S. leadership team brings strong guidance and insight to the North American marketplace, while staying true to Taiho’s legacy of developing the highest quality pharmaceuticals that improve the lives of people everywhere.

Headshot of Tim Whitten

Tim Whitten

President & CEO

Taiho Oncology, Inc.

Tim assumed the role of President & CEO in May 2018, having joined Taiho Pharma U.S.A., Inc. in February 2013 as Chief Commercial Officer. He is uniquely suited to the role, with an MBA and a pharmacy degree. Before joining Taiho, he served as President & CEO of Insmed, Inc., working to help patients with rare and serious lung diseases. Prior to Insmed, he was the President & CEO of Transave, Inc., and held senior management positions at Pharmacyclics and Bristol-Myers Squibb.

As the company’s first commercial hire, Tim oversaw the creation of the US commercial and Canadian businesses, with successful launches of LONSURF® (trifluridine and tipiracil) in both markets. Under his leadership, Taiho’s North American oncology commercial...

Headshot of Martin Birkhofer

Martin J. Birkhofer, M.D.

Senior Vice President and Chief Medical Officer

Taiho Oncology, Inc.

As Chief Medical Officer and Senior Vice President, Dr. Birkhofer is responsible for the Taiho Oncology Development organization, driving clinical development of our pipeline assets in all regions outside of Asia. His responsibilities also include Regulatory Affairs, Pharmacovigilance, CMC Formulation Development and Business Development.

A Medical Oncologist and accomplished leader in the oncology biopharmaceutical industry, Dr. Birkhofer has over 30 years of experience encompassing all phases of global clinical research & development with both small molecules and biologics. During the bulk of his career at Bristol-Myers Squibb, he held a variety of senior leadership roles in Clinical Development, Clinical Pharmacology, Medical Affairs and Business Development. In addition, he has...

Headshot of Michael Schick

Michael Schick

Senior Vice President, Chief Commercial Officer

Taiho Oncology, Inc.

Michael became Senior Vice President, Chief Commercial Officer in 2017, having started at Taiho Oncology as Vice President, Sales and Marketing in 2013. He has been working in oncology since 1996, and began his career in the pharmaceutical and biotech industry at Abbott Pharmaceuticals. He has since had roles of increasing responsibility at Bristol-Myers Squibb Oncology, Pharmacia Oncology, Pharmacyclics, Amgen, ImClone Systems, and Allos Therapeutics. Michael has a proven track record of leadership that has consistently delivered excellent business and people development results. He earned his Bachelor of Arts from Villanova University.

Headshot of Kazuhiko Okamoto

Kazuhiko Okamoto

Senior Vice President, Finance

Taiho Oncology, Inc.

Kazu has held a number of roles since joining Taiho Pharmaceutical Co., Ltd. in September 2009, culminating in his current position as Senior Vice President, Finance. During his tenure, he has also been responsible for Information Technology, Procurement and Human Resources. Kazu’s contributions have helped transform Taiho from a clinical development company to a fully integrated commercial organization.

Kazu has lent his talents to a diverse group of global semiconductor organizations, including Infineon Technologies and Oki Electric, based in Germany and Japan. He credits his leadership skills to his distinct set of professional and cultural experiences across the world, and he prides himself on a career spent bettering society.

Headshot of Juliet Agranoff

Juliet Agranoff

Senior Vice President, People

Taiho Oncology, Inc.

Juliet joined Taiho Oncology, Inc. as Senior Vice President, People in March 2019. Over the past decade, Juliet has brought her experience to specialty pharmaceutical firms such as The Medicines Company and Melinta Therapeutics, where she served as Senior Vice President and Head of Human Resources. Prior to that, she honed her talents and helped lead organizational change at a number of larger organizations including Pfizer, General Electric, Avon Products and Morgan Stanley.

With an inclusive, collaborative and empowering leadership style, Juliet leads the People function department at Taiho, and values her role in contributing to the growth of the company through building a foundation of credibility and trust.

Karin Blakolmer, MD, MBA

SENIOR VICE PRESIDENT & HEAD OF MEDICAL AFFAIRS

TAIHO ONCOLOGY, INC.

Karin joined Taiho in 2019 as Senior Vice President and Head of Taiho Oncology Medical Affairs. Karin’s responsibilities include leading publications, communications, medical information, investigator sponsored trials, medical information and education and real-world evidence generation.

Karin has 20 years of experience in medical oncology, including having held positions in early and late stage development at Roche and Novartis. In addition, she held European and global roles in Medical Affairs at Amgen, Sanofi. Prior to joining Taiho, Karin was the Head of Global Medical Affairs at Astellas.

Karin received her Doctorate of Medicine from the University of Graz, Austria and her MBA from ESSEC, Paris, France.

Headshot of Karim Benhadji

Karim Benhadji

Senior Vice President and Head of Clinical Development

Taiho Oncology, Inc.

Karim joined Taiho Oncology in January 2019 as Senior Vice President and Head of Clinical Development. Prior to this, Karim spent over 13 years with Eli Lilly and Company in oncology development roles of increasing responsibility. He was Vice President, Early Phase Oncology before joining Taiho Oncology and was in charge of a number of development programs in immuno-oncology.

Dr. Benhadji received his Doctorate of Medicine from the University of Oran. He has completed oncology fellowships in Universities of Oran and Paris and holds a Master of Science in Pharmacology and Therapeutics from the University of Paris 11.

STEPHEN E. YODER, MD, MBA

Vice President, Business Development

TAIHO ONCOLOGY, INC.

Steve joined Taiho Oncology Inc. as Vice President, Business Development in June 2020. In this newly created role, he is leading the company’s efforts to in-license and acquire additional oncology marketed products and late-stage development therapeutic candidates for treating solid tumors and hematological malignancies. These partnered assets will be added to Taiho Oncology’s expanding portfolio of internally-discovered candidates and approved products addressing the needs of cancer patients in North America.

Dr. Yoder received his Doctorate of Medicine from the University of Virginia and completed a residency in Internal Medicine at Pennsylvania Hospital in Philadelphia. He subsequently received a Masters of Business Administration in Health Care Management at the Wharton School, University of Pennsylvania. Steve has...

Headshot of Chris Jewell

Chris Jewell

Senior Vice President and General Counsel

Taiho Oncology, Inc.

Chris was promoted to Taiho Oncology, Inc.’s Senior Vice President and General Counsel in January 2020. Chris’ work in the legal department has assisted Taiho in transforming the legal function primarily from a development stage contracts department to its present structure of a fully capable legal function within the company. Prior to joining Taiho Oncology, Chris represented both domestic and global public and private life science and pharmaceutical companies having worked both in-house and in the business and finance unit of a large international firm. He holds each of a Bachelor of Arts from Wake Forest University, a Juris Doctorate from the Villanova University School of Law, and a Masters of Business Administration from the Villanova University College of Commerce and Finance.

Kathy Calarco

Vice President, Quality Assurance

TAIHO ONCOLOGY, INC.

Kathy joined Taiho Oncology, Inc. as Vice President, Quality in March 2020. Over the past 14 years, Kathy brought her experience to Johnson & Johnson Pharmaceutical, where she served as Head of Compliance, Scientific Systems and Laboratory Operations. Prior to that, she was part of Merck & Company supporting the Vaccine Division in various leadership roles in Laboratory and Quality.

With an energetic, collaborative and empowering leadership style, Kathy leads the Quality function department at Taiho, and values her role in contributing to the growth of the company through building a foundation of credibility and trust.

Kathy holds a Bachelor of Science degree from St. Joseph’s University, Philadelphia.

Ed Chapman

VICE PRESIDENT, Chief Information Officer

TAIHO ONCOLOGY, INC.

Ed became Vice President, Chief Information Officer in 2020. He started at Taiho Oncology in 2013 as Sr. Director, IT and later became VP, IT in 2016. As the first member of the Taiho Oncology IT organization, he has built a team that provides and supports innovative technology solutions, infrastructure, service desk, validation, cyber security, and data privacy for all regions outside of Asia. His responsibilities also include Facilities. He began his career with Electronic Data Systems (EDS) as an Advanced System Engineer before working in technical sales, which led him to the biopharmaceutical industry. He has since held roles of increasing responsibility at Celgene, Immunomedics, and Taiho Oncology.

Ed graduated from California State University with a Bachelor of Science in Accounting and Management Information...

Kimberly S. Stranick, PhD

Senior Vice President, Regulatory Affairs

TAIHO ONCOLOGY, INC.

Kimberly joined Taiho Oncology as Senior Vice President, Regulatory Affairs in September, 2020. She has more than 20 years of experience in global regulatory affairs in the pharmaceutical industry, successfully leading global organizations by performing regulatory activities and providing strategic guidance for teams in support of small molecule and biologic development programs, as well as combination drugs and over-the-counter medicines.

As the leader of Regulatory Affairs for Taiho, Kimberly is responsible for global Health Authority interactions and submissions to support the development of pipeline assets, including successful clinical trial registration and conduct, labeling agreements, product approvals and marketed product life cycle support.

Before joining Taiho, Dr. Stranick held senior management roles...